Related Experiment Video
Updated: Jul 29, 2025
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.1K
DA7R: A 7-Letter Zip Code to Target PDAC
Sofia Parrasia1, Andrea Rossa2, Nicola Roncaglia2,3
1Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy.
Pharmaceutics
|May 27, 2023
Summary
Researchers explored using A7R peptide conjugates for pancreatic cancer targeting. The A7R peptide successfully delivered anticancer compounds to pancreatic ductal adenocarcinoma cells, showing promise for improved cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Delivery
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable cancer.
- Novel therapeutic strategies are urgently needed for PDAC treatment.
- Peptides offer targeted delivery by binding to cancer cell surface proteins.
Purpose of the Study:
- To evaluate A7R peptide-drug conjugates as a targeting strategy for PDAC.
- To assess the potential of A7R to deliver the anticancer compound PAPTP to PDAC cells.
Main Methods:
- Designed A7R peptide derivatives (DA7R, cA7R) with bioreversible linkers and PAPTP cargo.
- Introduced a tetraethylene glycol chain to enhance solubility.
- Investigated uptake of fluorescent DA7R conjugates and PAPTP-DA7R derivatives in PDAC cell lines.
Main Results:
- Uptake of DA7R conjugates correlated with neuropilin-1 (NRP-1) and VEGFR2 expression in PDAC cells.
- The PAPTP-DA7R derivative demonstrated targeted delivery to PDAC cells.
Conclusions:
- A7R-drug conjugates show potential for targeted drug delivery in PDAC.
- This approach could enhance therapeutic efficacy and reduce side effects.
- Further development of A7R conjugates for PDAC therapy is warranted.
